Home › Compare › ARTH vs DIVO

ARTH vs DIVO: Dividend Comparison 2026

ARTH yields 2000000.00% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARTH wins by $4.879226400974806e+39M in total portfolio value
10 years
ARTH
ARTH
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full ARTH calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — ARTH vs DIVO

📍 ARTH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARTHDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARTH + DIVO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ARTH pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARTH
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, ARTH beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARTH + DIVO for your $10,000?

ARTH: 50%DIVO: 50%
100% DIVO50/50100% ARTH
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARTH right now

ARTH
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-103.9
Piotroski
3/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARTH buys
0
DIVO buys
0
No recent congressional trades found for ARTH or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARTHDIVO
Forward yield2000000.00% ✓6.49%
Annual dividend / share$2.00$2.91 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.879226400974806e+39M$30.7K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$981.68
Total dividends collected$4.879195005460081e+39M$8.2K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ARTH vs DIVO ($10,000, DRIP)

YearARTH PortfolioARTH Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,349$649.42+$200.00M → ARTH
2$3,738,731,768,458$3,738,517,757,009.35$12,833$688.83+$3738731.76M → ARTH
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,459$727.90+$65315062866.92M → ARTH
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$16,238$766.49+$1066400830062625.00M → ARTH
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$18,179$804.47+$16272182796453826560.00M → ARTH
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$20,293$841.71+$2.3205424011366188e+23M → ARTH
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$22,591$878.14+$3.0927990661046884e+27M → ARTH
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$25,087$913.65+$3.8524105697352695e+31M → ARTH
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$27,791$948.18+$4.484688260147987e+35M → ARTH
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$30,718$981.68+$4.879226400974806e+39M → ARTH

ARTH vs DIVO: Complete Analysis 2026

ARTH — Stock

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Full ARTH Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this ARTH vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARTH vs SCHDARTH vs JEPIARTH vs OARTH vs KOARTH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.